Ignite Creation Date:
2024-05-06 @ 4:07 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04874831
Status:
WITHDRAWN
Last Update Posted:
2021-11-18
First Post:
2021-04-15
Brief Title:
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma MERKLIN 1
Sponsor:
4SC AG
Organization:
4SC AG
Study Overview
Official Title:
A Phase II Open Label Multicenter Study to Investigate the Efficacy and Safety of Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma - the MERKLIN 1 Study
Status:
WITHDRAWN
Status Verified Date:
2021-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Refocusing of sponsors clinical development program No safety concern or change of the risk-benefit assessment of the investigational medicinal product has led to this decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial studies how well domatinostat 4SC-202 works in combination with avelumab in adult patients with treatment-naïve metastatic Merkel Cell Carcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2019-003575-19 | EUDRACT_NUMBER | None | None |